Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Modalis Therapeutics Corporation ( (JP:4883) ) just unveiled an update.
Modalis Therapeutics Corporation announced a non-operating expense of 35 million yen due to foreign exchange losses for the first half of 2025. This financial impact was primarily due to the revaluation of foreign currency denominated assets and liabilities, which may affect the company’s earnings as detailed in their financial results.
More about Modalis Therapeutics Corporation
Modalis Therapeutics Corporation is a company listed on the Tokyo Stock Exchange, focusing on the biotechnology industry. It specializes in developing innovative therapies, with a market focus on genetic and molecular treatments.
Average Trading Volume: 5,097,750
Technical Sentiment Signal: Sell
Current Market Cap: Yen7.08B
For a thorough assessment of 4883 stock, go to TipRanks’ Stock Analysis page.